Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
Total Valuation
Enanta Pharmaceuticals has a market cap or net worth of $402.34M. The enterprise value is $268.11M.
Market Cap$402.34M
Enterprise Value$268.11M
Share Statistics
Enanta Pharmaceuticals has 28,862,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,862,600
Owned by Insiders4.98%
Owned by Institutions13.14%
Financial Efficiency
Enanta Pharmaceuticals’s return on equity (ROE) is -1.27 and return on invested capital (ROIC) is -31.44%.
Return on Equity (ROE)-1.27
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-31.44%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee498.66K
Profits Per Employee-625.11K
Employee Count131
Asset Turnover0.23
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enanta Pharmaceuticals is ―. Enanta Pharmaceuticals’s PEG ratio is 0.10.
PE Ratio―
PS Ratio3.91
PB Ratio3.95
Price to Fair Value3.95
Price to FCF-7.94
Price to Operating Cash Flow-12.86
PEG Ratio0.10
Income Statement
In the last 12 months, Enanta Pharmaceuticals had revenue of 65.32M and earned -81.89M in profits. Earnings per share was -3.84.
Revenue65.32M
Gross Profit65.32M
Operating Income-85.35M
Pretax Income-83.55M
Net Income-81.89M
EBITDA-70.78M
Earnings Per Share (EPS)-3.84
Cash Flow
In the last 12 months, operating cash flow was -23.18M and capital expenditures -20.39M, giving a free cash flow of -43.57M billion.
Operating Cash Flow-23.18M
Free Cash Flow-43.57M
Free Cash Flow per Share-1.51
Dividends & Yields
Enanta Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.42
52-Week Price Change62.09%
50-Day Moving Average10.98
200-Day Moving Average7.92
Relative Strength Index (RSI)72.49
Average Volume (3m)412.23K
Important Dates
Enanta Pharmaceuticals upcoming earnings date is Feb 9, 2026, After Close (Confirmed).
Last Earnings DateNov 17, 2025
Next Earnings DateFeb 9, 2026
Ex-Dividend Date―
Financial Position
Enanta Pharmaceuticals as a current ratio of 4.21, with Debt / Equity ratio of 310.67%
Current Ratio4.21
Quick Ratio4.21
Debt to Market Cap0.57
Net Debt to EBITDA-2.22
Interest Coverage Ratio-11.11
Taxes
In the past 12 months, Enanta Pharmaceuticals has paid -1.66M in taxes.
Income Tax-1.66M
Effective Tax Rate0.02
Enterprise Valuation
Enanta Pharmaceuticals EV to EBITDA ratio is -5.59, with an EV/FCF ratio of -13.19.
EV to Sales6.49
EV to EBITDA-5.59
EV to Free Cash Flow-13.19
EV to Operating Cash Flow-22.01
Balance Sheet
Enanta Pharmaceuticals has $204.11M in cash and marketable securities with $207.10M in debt, giving a net cash position of -$2.99M billion.
Cash & Marketable Securities$204.11M
Total Debt$207.10M
Net Cash-$2.99M
Net Cash Per Share-$0.10
Tangible Book Value Per Share$3.03
Margins
Gross margin is 76.85%, with operating margin of -130.65%, and net profit margin of -125.36%.
Gross Margin76.85%
Operating Margin-130.65%
Pretax Margin-127.90%
Net Profit Margin-125.36%
EBITDA Margin-116.14%
EBIT Margin-116.14%
Analyst Forecast
The average price target for Enanta Pharmaceuticals is $17.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.00
Price Target Upside21.95% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-3.42%
EPS Growth Forecast30.03%